Michigan Biosciences Industry Association Logo

Federal Advocacy

Stay updated on federal initiatives and policies influencing the bio-industry across the country. This category highlights national-level advocacy efforts, initiatives, and developments driving innovation and growth across the industry.

Advocacy Advocacy : Federal Advocacy Advocacy : State Advocacy Association Updates BioConnections® Jobs Event Event : Industry Event Event : MichBio Advocacy Events Event : MichBio Networking Event Event : MichBio Signature Event Event : MichBio Webinar Event : Partner Event Member Feature News News : Industry News News : Member News News : MichBio News/Statement News : Michigan News
Codifying MFN Drug Pricing Could Undermine Biopharma Innovation
Posted In: Federal Advocacy,
Date posted Feb 20

As Congress considers whether to codify Most Favored Nation (MFN) drug pricing into statute, recent comments by CMS Administrator Dr. Mehmet Oz...

Read Post
FDA to Adopt Single-trial Default Policy: Implications for Biopharma and Vaccine Innovation
Posted In: Federal Advocacy,
Date posted Feb 20

The U.S. Food and Drug Administration (FDA) has announced a significant shift in its drug approval standards, moving away from the long-standing...

Read Post
How NIH’s New Funding Philosophy Shapes Innovation & U.S. Competitiveness
Posted In: Federal Advocacy,
Date posted Feb 6

The January 30, 2026 announcement of a Unified NIH Funding Strategy marks one of the most consequential shifts in federal biomedical research...

Read Post
More NIH: Director Rebuts Accusations of Grant Cancellations and Clinical-trial Disruptions
Posted In: Federal Advocacy,
Date posted Feb 6

National Institutes of Health (NIH) Director Dr. Jayanta “Jay” Bhattacharya faced a pointed round of bipartisan scrutiny at a Senate...

Read Post
Congress Advances Rare Disease & Cancer Innovation
Posted In: Federal Advocacy,
Date posted Feb 6

In overlapping victories for biotech innovation and public health, the U.S. Senate and House of Representatives have approved two landmark pieces...

Read Post
Government Funding Package Moves to Senate: What the Health Provisions Mean for the Bio-Industry
Posted In: Federal Advocacy,
Date posted Jan 26

A sweeping government funding package now before the U.S. Senate carries major implications for the life sciences sector - touching drug...

Read Post
MFN Pricing and the Quiet Surrender of U.S. Biotech Leadership
Posted In: Federal Advocacy,
Date posted Jan 26

The recent White House announcement of “The Great Healthcare Plan” landed with familiar fanfare: bold promises to lower drug prices,...

Read Post
Rare Disease Investment "Rebound" After IRA Orphan-Drug Change - and the Debate it Reginites
Posted In: Federal Advocacy,
Date posted Jan 26

A coalition of life sciences investors, Incubate, says capital is beginning to flow back into rare disease drug development, citing more than $1...

Read Post
Federal Fly-In Season to Begin — Two Opportunities to Engage
Posted In: Federal Advocacy,
Date posted Jan 13

MichBio invites Michigan’s bio-industry community to join two upcoming federal legislative fly-ins in Washington, DC, offering direct...

Read Post
BIO Call for Predictable, Pro-innovation Federal Policy in Response to OSTP RFI
Posted In: Federal Advocacy,
Date posted Jan 13

In a detailed response to the White House Office of Science and Technology Policy (OSTP), the Biotechnology Innovation Organization (BIO) urged...

Read Post
FDA Signals Innovation-Friendly Shift on AI and Wearables
Posted In: Federal Advocacy,
Date posted Jan 13

This month, the U.S. Food and Drug Administration (FDA) took a notable step toward modernizing oversight of digital health technologies -...

Read Post
HHS Lends Support to Stalled "Give Kids a Chance" Legislation
Posted In: Federal Advocacy,
Date posted Jan 13

The U.S. Department of Health and Human Services (HHS) has formally lent its support to the Give Kids A Chance Act - landmark legislation...

Read Post